Millennium Velcade Multiple Myeloma Launch Expected In Late 2003
Millennium expects FDA approval of the proteasome inhibitorVelcade for multiple myeloma in the second half of 2003 based on Phase II data
Millennium expects FDA approval of the proteasome inhibitorVelcade for multiple myeloma in the second half of 2003 based on Phase II data